CONTRAINDICATIONS
Paclitaxel is
contraindicated in patients who have a history of hypersensitivity
reactions to paclitaxel, or other drugs formulated in polyoxyethylated
castor oil. Paclitaxel should not be used in patients with solid
tumors who have baseline neutrophil counts of < 1,500 cells/mm3.
WARNINGS
Anaphylaxis
and severe hypersensitivity reactions characterized by dyspnea
and hypotension requiring treatment, angioedema, and generalized
urticaria have occurred in 2% of patients receiving paclitaxel injection
in clinical trials. Fatal reactions have occurred in patients despite
premedication. All patients should be pretreated with corticosteroids,
diphenhydramine, and H2
antagonists.
(See DOSAGE AND ADMINISTRATION Section). Patients who experience
severe hypersensitivity reactions to paclitaxel should not be rechallenged
with the drug.
Bone marrow suppression (primarily neutropenia) is dose-dependent
and is the dose-limiting toxicity. Neutrophil nadirs occurred at
a median of 11 days. Paxlitaxel should not be administered to patients
with baseline neutrophil counts of less than <(primarily neutropenia)
is dose-dependent and is the dose-limiting toxicity. Neutrophil
nadirs occurred at a median of 11 days. Paclitaxel should not be
administered to patients with baseline neutrophil counts of less
than 1,500 cells/mm3. Frequent monitoring of blood counts should
be instituted during paclitaxel treatment. Patients should not be
re-treated with subsequent cycles of paclitaxel until neutrophils
recover to a level >1,500 cells/mm3 . Frequent monitoring
of blood counts should be instituted during paclitaxel treatment.
Patients should not be re-treated with subsequent cycles of paclitaxel
until neutrophils recover to a level >1,500 cells/mm3
and platelets recover to a level 100,000 cells/mm3.
Severe conduction
abnormalities have been documented in <1% patients during paclitaxel
therapyand in some cases requiring pacemaker placement. If patients
develop significant conduction abnormalities during paclitaxel infusion,
appropriate therapy should be administered and continuous cardiac
monitoring should be performed during subsequent therapy with paclitaxel.<1%
of patients during paclitaxel therapy and in some cases requiring
pacemaker placement. If patients develop significant conduction
abnormalities during paclitaxel infusion, appropriate therapy should
be administered and continuous cardiac monitoring should be performed
during subsequent therapy with paclitaxel.>
Pregnancy:
Paclitaxel may cause fetal harm when administered to a pregnant
woman. Administration of paclitaxel during the period of organogenesis
to rabbits at doses of 3 mg/kg/day (about 0.2 the daily maximum
recommended human dose on a mg/m2 basis) caused embryo-
and fetotoxicity, as indicated by intrauterine mortality, increased
resorptions and increased fetal deaths. Maternal toxicity was also
observed at this dose. No teratogenic effects were observed at 1
mg/kg/day (about 1/15 the daily maximum recommended human dose on
a mg/m2 basis); teratogenic potential could not be assessed
at higher doses due to extensive fetal mortality.
There are no
adequate and well-controlled studies in pregnant women. If paclitaxel
is used during pregnancy, or if the patient becomes pregnant while
receiving this drug, the patient should be apprised of the potential
hazard to the fetus. Women of childbearing potential should be advised
to avoid becoming pregnant.
PRECAUTIONS
Contact of the undiluted concentrate with plasticized polyvinyl
chloride (PVC) equipment or devices used to prepare solutions for
infusion is not recommended. In order to minimize patient exposure
to the plasticizer DEHP [di-(2-ethylhexyl)phthalate], which may
be leached from PVC infusion bags or sets, diluted paclitaxel solutions
should preferably be stored in bottles (glass, polypropylene) or
plastic bags (polypropylene, polyolefin) and administered through
polyethylene-lined administration sets.
Paclitaxel should
be administered through an in-line filter with a microporous membrane
not greater than 0.22 microns. Use of filter devices such as IVEX-2Ò
filters which incorporate short inlet and outlet PVC-coated tubing
has not resulted in significant leaching of DEHP.
Drug
Interactions: In a Phase 1 trial using escalating doses
of paclitaxel (110 to 200 mg/m2) and cisplatin (50 to
75 mg/m2) given as sequential infusions, myelosuppression
was more profound when paclitaxel was given after cisplatin than
with the alternate sequence (i.e., paclitaxel before cisplatin).
Pharmacokinetic data from these patients demonstrated a decrease
in paclitaxel clearance of approximately 33% when paclitaxel injection
was administered following cisplatin.
The metabolism
of paclitaxel is catalyzed by cytochrome P450 isoenzymes CYP2CB
and CYP3A4. In the absence of formal clinical drug interaction studies,
caution should be exercised when administering paclitaxel concomitantly
with known substrates or inhibitors of the cytochrome P450 isoenzymes
CYP2CB and CYP3A4. (See CLINICAL PHARMACOLOGY Section.)
Potential interactions
between paclitaxel, a substrate of CYP3A4 and protease inhibitors
(ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates
and/or inhibitors of CYP3A4 have not been evaluated in clinical
trials.
Reports in the
literature suggest that plasma levels of doxorubicin (and its active
metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin
are used in combination.
Hematology:
Paclitaxel therapy should not be administered to patients with baseline
neutrophil counts of less than 1,500 cells/mm3. In order
to monitor the occurrence of myelotoxicity, it is recommended that
frequent peripheral blood cell counts be performed on all patients
receiving paclitaxel. Patients should not be re-treated with subsequent
cycles of paclitaxel until neutrophils recover to a level 1,500
cells/mm3 and platelets recover to a level 100,000 cells/mm3.
In the case of severe neutropenia (<500 cells/mm3
for seven days or more) during a course of paclitaxel therapy, a
20% reduction in dose for subsequent courses of therapy is recommended.
Hypersensitivity
Reactions: Patients with a history of severe hypersensitivity
reactions to products containing polyoxyethylated castor oil (e.g.,
cyclosporin for injection concentrate and teniposide for injection
concentrate) should not be treated with paclitaxel. In order to
avoid the occurrence of severe hypersensitivity reactions, all patients
treated with paclitaxel should be premedicated with corticosteroids
(such as dexamethasone), diphenhydramine and H2 antagonists
(such as cimetidine or ranitidine). Minor symptoms such as flushing,
skin reactions, dyspnea, hypotension or tachycardia do not require
interruption of therapy. However, severe reactions, such as hypotension
requiring treatment, dyspnea requiring bronchodilators, angioedema
or generalized urticaria require immediate discontinuation of paclitaxel
and aggressive symptomatic therapy. Patients who have developed
severe hypersensitivity reactions should not be rechallenged with
paclitaxel.
Cardiovascular:
Hypotension, bradycardia and hypertension have been observed during
administration of paclitaxel, but generally do not require treatment.
Occasionally paclitaxel infusion must be interrupted or discontinued
because of initial or recurrent hypertension. Frequent vital
sign monitoring, particularly during the first hour of paclitaxel
infusion, is recommended. Continuous cardiac monitoring is not required
except for patients with serious conduction abnormalities. (See
WARNINGS Section.)
Nervous
System: Although, the occurrence of peripheral neuropathy
is frequent, the development of severe symptomatology is unusual
and requires a dose reduction of 20% for all subsequent courses
of paclitaxel.
Paclitaxel contains
dehydrated alcohol USP, 396 mg/mL; consideration should be given
to possible CNS and other effects of alcohol. (See PRECAUTIONS -
Pediatric Use Section).
Hepatic: There is evidence that the toxicity
of paclitaxel is enhanced in patients with elevated liver enzymes.
Caution should be exercised when administering paclitaxel to patients
with moderate to severe hepatic impairment and dose adjustments
should be considered.
Injection
Site Reaction: Injection site reactions, including
reactions secondary to extravasation, were usually mild and consisted
of erythema, tenderness, skin discoloration, or swelling at the
injection site. These reactions have been observed more frequently
with the 24 hour infusion than with the 3 hour infusion. Recurrence
of skin reactions at a site of previous extravasation following
administration of paclitaxel at a different site, i.e., "recall"
as been reported rarely.
Rare reports
of more severe events such as phlebitis, cellulitis, induration,
skin exfoliation, necrosis, and fibrosis have been received as part
of the continuing surveillance of paclitaxel safety. In some cases
the onset of the injection site reaction either occurred during
a prolonged infusion or was delayed by a week to ten days.
A specific treatment
for extravasation reactions is unknown at this time. Given the possibility
of extravasation, it is advisable to closely monitor the infusion
site for possible infiltration during drug administration.
Carcinogenesis,
Mutagenesis, and Impairment of Fertility: The carcinogenic
potential of paclitaxel has not been studied.
Paclitaxel
has been shown to be clastogenic in vitro (chromosome aberrations
in human lymphocytes) and in vivo (micronucleus test in mice).
Paclitaxel was not mutagenic in the Ames test or CHO/HGPRT gene
mutation assay. Administration of paclitaxel prior to
and during mating produced impairment of fertility in male and female
rats at doses equal to or greater than 1 mg/kg/day (about 0.04 the
daily maximum recommended human dose on a mg/m2 basis).
At this dose, paclitaxel caused reduced fertility and reproductive
indices, and increase embryo- and fetotoxicity (See WARNINGS Section).
Pregnancy:
Teratogenic Effects, Pregnancy Category D (See WARNINGS Section.)
Nursing
Mothers: It is not known whether the drug is excreted
in human milk. Following intravenous administration of carbon-14
labeled paclitaxel to rats on days 9 to 10 postpartum, milk concentrations
of radioactivity exceeded and declined in parallel with the plasma
concentrations. Because many drugs are excreted in human milk
and because of the potential for serious adverse reactions in nursing
infants, it is recommended that nursing be discontinued when receiving
paclitaxel therapy.
Pediatric
Use: The safety and effectiveness of paclitaxel in
padiatric patients have not been established.
There have been
reports of central nervous system (CNS) toxicity in an ongoing investigational
clinical trial in pediatric patients in which paclitaxel was infused
intravenously over 3 hours at doses ranging from 350 mg/m2
to 420 mg/m2. The toxicity is most likely attributable
to the high dose of the ethanol component of the paclitaxel vehicle
given over a short infusion time. The use of concomitant antihistamines
may intensify this effect. Although a direct effect of the paclitaxel
itself cannot be discounted, the high doses used in this study (over
twice the recommended adult dosage) must be considered in assessing
the safety of paclitaxel for use in this population.
Adverse
Reactions
Data in the following table are based on the experience of 812 patients
(493 with ovarian carcinoma and 319 with breast carcinoma) enrolled
in 10 studies. Two hundred and seventy-five patients were treated
in 8 Phase 2 studies with paclitaxel doses ranging from 135 to 300
mg/m2 administered over 24 hours (in 4 of these studies,
G-CSF was administered as hematopoietic support). Three hundred
and one patients were treated in the randomized Phase 3 ovarian
carcinoma study which compared two doses (135 or 175 mg/m2)
and two schedules (3 or 24 hours) of paclitaxel. Two hundred and
thirty-six patients with breast carcinoma received paclitaxel (135
or 175 mg/m2) administered over 3 hours in a controlled
study.
TABLE 6: SUMMARY
OF ADVERSE EVENTS IN 812 PATIENTS RECEIVING PACLITAXEL
|
|
%INCIDENCE |
Bone
Marrow: |
|
|
-Neutropenia |
<2,000/mm3
<500/mm3 |
90
52 |
-Leukopenia |
<4,000/mm3
<1,000/mm3 |
90
17 |
-Thrombocytopenia |
<100,000/mm3
<50,000/mm3 |
20
7 |
-Anemia |
<11
g/dL
<8 g/dL |
78
16 |
-Infections |
|
30 |
-Bleeding |
|
14 |
-Red
Cell Transfusions |
|
25 |
-Platelet
Transfusions |
|
2 |
Hypersensitivity
Reaction* : |
|
|
-All |
|
41 |
-Severe |
|
2 |
Cardiovascular: |
|
|
-Vital
Sign Changes** |
|
|
-Bradycardia
(N=537) |
|
3 |
-Hypotension
(N=532) |
|
12 |
-Significant
Cardiovascular Events |
|
1 |
Abnormal
Ecg: |
|
|
-All
Pts |
|
23 |
-Pts
with normal baseline (N=559) |
|
14 |
Peripheral
Neuropathy: |
|
|
-Any |
|
60 |
-Severe |
|
3 |
Myalgia/Arthralgia: |
|
|
-Any |
|
60 |
-Severe |
|
8 |
Gastrointestinal: |
|
|
-Nausea
and Vomiting |
|
52 |
-Diarrhea |
|
38 |
-Mucositis |
|
31 |
Alopecia |
|
87 |
Hepatic:(Pts
with normal baseline and on study data) |
|
|
-Bilirubin
elevations (N=765) |
|
7 |
-Alkaline
phosphotase elevations (N=575) |
|
22 |
-AST
(SGOT) elevations (N=591) |
|
19 |
Injection
Site Reaction |
|
13 |
* All Patients
received premedication
** During the first 3 hours of infusion
None of the
observed toxicities were clearly influenced by age.
The following
discussion refers to the overall safety database of 812 patients
with solid tumors treated in clinical studies. The frequency and
severity of adverse events have been generally similar for patients
receiving paclitaxel for the treatment of ovarian or breast carcinoma.
The frequency and severity of important adverse events for the Phase
3 ovarian and breast carcinoma studies are presented in tabular
form by treatment arm in the "CLINICAL PHARMACOLOGY - Clinical
Studies" Section.
Hematologic:
Bone marrow suppression were the major dose-limiting toxicity of
paclitaxel. Neutropenia, the most important hematologic toxicity,
was dose and schedule dependent and was generally rapidly reversible.
Among patients treated in the Phase 3 ovarian study with a 3 hour
infusion, neutrophil counts decline below 500 cells/mm3
in 13% of the patients treated with a dose of 135 mg/m2
compared to 27% at a dose of 175 mg/m2 (p=0.05). In the
same study, severe neutropenia (<500 cells/mm3) was
more frequent with the 24 hour than with the 3 hour infusion; infusion
duration had a greater impact on myelosuppression than dose. Neutropenia
did not appear to increase with cumulative exposure and did not
appear to be more frequent nor more severe for patients previously
treated with radiation therapy.
Fever was frequent
(12% of all treatment courses). Infectious episodes occurred in
30% of all patients and 9% of all courses; these episodes were fatal
in 1% of all patients, and included sepsis, pneumonia and peritonitis.
In the Phase 3 ovarian study, infectious episodes were reported
in 19% of the patients given either 135 or 175 mg/m2
dose by a 3 hour infusion. Urinary tract infections and upper respiratory
tract infections were the most frequently reported infectious complications.
Thrombocytopenia
was uncommon, and almost never severe (<50,000 cells/mm3).
Twenty percent of the patients experienced a drop in their platelet
count below 100,000 cells/mm3 at least once while on
treatment; 7% had a platelet count <50,000 cells/mm3
at the time of their worst nadir. Among the 812 patients, bleeding
episodes were reported in 4% of all courses and by 14% of all patients
but most of the hemorrhagic episodes were localized and the frequency
of these events was unrelated to the paclitaxel dose and schedule.
In the Phase 3 ovarian study, bleeding episodes were reported in
10% of the patients receiving either the 135 or 175 mg/m2
dose given by a 3 hour infusion; no patients treated with the 3
hour infusion received platelet transfusions.
Anemia (Hb <11
g/dL) was observed in 78% of all patients and was severe (Hb <8
g/dL) in 16% of the cases. No consistent relationship between dose
or schedule and frequency of anemia was observed. Among all patients
with normal baseline hemoglobin, 69% became anemic on study but
only 7% had severe anemia. Red cell transfusions were required in
25% of all patients and in 12% of those with normal baseline hemoglobin
levels.
Hypersensitivity
Reactions (HSRs): All patients received premedication
prior to paclitaxel (See WARNINGS and PRECAUTIONS - Hypersensitivity
Reactions Sections). The frequency and severity of HSRs were not
affected by the dose or schedule of paclitaxel administration. In
the Phase 3 ovarian study the 3 hour infusion was not associated
with a greater increase in HSRs when compared to the 24 hour infusion.
Hypersensitivity reactions were observed in 20% of all courses and
in 41% of all patients. These reactions were severe in less than
2% of the patients and 1% of the courses. No severe reactions were
observed after course 3 and severe symptoms occurred generally within
the first hour of paclitaxel infusion. The most frequent symptoms
observed during these severe reactions were dyspnea, flushing, chest
pain and tachycardia.
The minor hypersensitivity
reactions consisted mostly of flushing (28%), rash (12%), hypotension
(4%), dyspnea (2%), tachycardia (2%) and hypertension (1%). The
frequency of hypersensitivity reactions remained relativity stable
during the entire treatment period.
Cardiovascular:
Hypotension, during the first 3 hours of infusion,
occurred in 12% of all patients and 3% of all courses administered.
Bradycardia, during the first 3-hours of infusion, occurred in 3%
of all patients and 1% of all courses. In Phase 3 ovarian study,
neither dose nor schedule had an effect on the frequency of hypotension
and bradycardia. These vital sign changes most often caused no symptoms
and required neither specific therapy nor treatment discontinuation.
The frequency of hypotension and bradycardia were not influenced
by prior anthracycline therapy.
Significant
cardiovascular events possibly related to paclitaxel occurred in
approximately 1% of all patients. These events included syncope,
rhythm abnormalities, hypertension and venous thrombosis. One of
the patients with syncope treated with paclitaxel at 175 mg/m2
over 24 hours had progressive hypotension and died. The arrhythmias
included asymptomatic ventricular tachycardia, bigeminy and complete
AV block requiring pacemaker placement.
Electrocardiogram
(ECG) abnormalities were common among patients at baseline. ECG
abnormalities on study did not usually result in symptoms, were
not dose-limiting, and required no intervention. ECG abnormalities
were noted in 23% of all patients. Among patients with a normal
ECG prior to study entry, 14% of all patients developed an abnormal
tracing while on study. The most frequently reported ECG modifications
were non- specific repolarization abnormalities, sinus bradycardia,
sinus tachycardia and premature beats. Among patients with normal
ECG at baseline, prior therapy with anthracylines did not influence
the frequency of ECG abnormalities.
Cases of myocardial
infarction have been reported rarely. Congestive heart failure has
been reported typically in patients who have received other chemotherapy,
notably anthracyclines. (See PRECAUTIONS - Drug Interactions Section.)
Rare reports
of atrial fibrillation and supraventricular tachycardia have been
received as part of the continuing surveillance of pacliraxel safety.
Respiratory:
Rare reports of interstitial pneumonia, lung fibrosis and
pulmonary embolism have been received as part of the continuing
surveillance of paclitaxel safety.
Neurologic:
The frequency and severity of neurologic manifestations
were dose-dependent, but were not influenced by infusion duration.
Peripheral neuropathy was observed in 60% of all patients (3% severe)
and in 52% (2% severe) of the patients without pre-existing neuropathy.
The frequency
of peripheral neuropathy increased with cumulative dose. Neurologic
symptoms were observed in 27% of the patients after the first course
of treatment and 34 to 51% from 2 to 10.
Peripheral neuropathy
was the cause of paclitaxel discontinuation in 1% of all patients.
Sensory symptoms have usually improved or resolved within several
months of paclitaxel discontinuation. The incidence of neurologic
symptoms did not increase in the subset of patients previously treated
with cisplatin. Pre-existing neuropathies resulting from prior therapies
are not a contraindication for paclitaxel therapy. Other
than peripheral neuropathy, serious neurologic events following
paclitaxel administration have been rare (<1%) and have included
grand mal seizures, syncope, ataxia and neuroencephalopathy.
Rare reports
of autonomic neuropathy resulting in paralytic ileus have been received
as part of the continuing surveillance of paclitaxel safety. Optic
nerve and/or visual disturbances (scintillating scotomata) have
also been reported, particularly in patients who have received higher
dose than those recommended. These effects generally have been reversible.
However,rare reports in the literature of abnormal visual evoked
potentials in patients have suggested persistent optic nerve damage.
Arthralgia/Myalgia:
There was no consistent relationship between dose or
schedule of paclitaxel and the frequency or severity of arthralgia/myalgia.
Sixty percent of all patients treated experienced arthralgia/myalgia;
8% experienced severe symptoms. The symptoms were usually transient,
occurred two or three days after paclitaxel administration, and
resolved within a few days. The frequency and severity of musculoskeletal
symptoms remained unchanged throughout the treatment period.
Hepatic:
No relationship was observed between liver function abnormalities
and either dose or schedule of paclitaxel administration. Among
patients with normal baseline liver function 7%, 22% and 19% had
elevations in bilirubin, alkaline phosphatase and AST (SGOT), respectively.
Prolonged exposure to paclitaxel was not associated with cumulative
hepatic toxicity.
Rare reports
of hepatic necrosis and hepatic encephalopathy leading to death
have been received as part of the continuing surveillance of paclitaxel
safety.
Gastrointestinal
(GI): Nausea/vomiting, diarrhea and mucositis were
reported by 52%, 38% and 31% of all patients, respectively. These
manifestations were usually mild to moderate. Mucositis was schedule
dependent and occurred more frequently with the 24 hour than with
the 3 hour infusion.
Rare reports
of intestinal obstruction, intestinal perforation, pancreatitis,
ischemic colitis and dehydration have been received as part of the
continuing surveillance of paclitaxel safety. Rare reports of neutropenic
enterocolitis (typhlitis), despite the coadministration of G-CSF,
were observed in patients treated with paclitaxel alone and in combination
with other chemotherapeutic agents.
Injection
Site Reaction: Injection site reactions, including
reactions secondary to extravasation, were usually mild and consisted
of erythema, tenderness, skin discoloration, or swelling at the
injection site. These reactions have been observed more frequently
with 24 hour infusion than with 3 hour infusion. Recurrence of skin
reactions at a site of previous extravasation following administration
of pacliraxel at a different site, i.e., "recall", has
been reported rarely.
Rare reports
of more severe events such as phlebitis, cellulitis, induration,
skin exfoliation, necrosis, and fibrosis have been received as part
of the continuing surveillance of paclitaxel safety. In some cases
the onset of the injection site reaction either occurred during
a prolonged infusion or was delayed by a week to ten days.
A specific treatment
for extravasation reactions is unknown at this time. Given the possibility
of extravasation, it is advisable to closely monitor the infusion
site for possible infiltration during drug administration.
Other
Clinical Events: Alopecia was observed in almost all
(87%) of the patients. Transient skin changes due to paclitaxel
related hypersensitivity reactions have been observed, but no other
skin toxicities were significantly associated with paclitaxel administration.
Nail changes (changes in pigmentation or discoloration of nail bed)
were uncommon (2%). Edema was reported in 21% of all patients (17%
of those without baseline edema); only 1% had severe edema and none
of these patients required treatment discontinuation. Edema was
most commonly focal and disease-related. Edema was observed in 5%
of all courses for patients with normal baseline and did not increase
with time on study.
Rare reports
of skin abnormalities related to radiation recall have been received
as part of the continuing surveillance of paclitaxel safety.
Rare reports
of radiation pneumonitis have been received in patients receiving
concurrent radiotherapy.
Accidental
Exposure: Upon inhalation, dyspnea, chest pain, burning
eyes, sore throat and nausea have been reported. Following topical
exposure, events have included tingling, burning and redness.
OVERDOSAGE
There is no
known antidote for paclitaxel overdosage. The primary anticipated
complications of overdosage would consist of bone marrow suppression,
peripheral neurotoxicity and mucositis.
DOSAGE
AND ADMINISTRATION
Note: Contact
of the undiluted concentrate with plasticized PVC equipment or devices
used to prepare solutions for infusion is not recommended. In order
to minimize patient exposure to the plasticizer DEHP [di-(2- ethylhexyl)phthalate],
which may be leached from PVC infusion bags or sets, diluted paclitaxel
solutions should be stored in bottles (glass, propylene) or plastic
bags (polypropylene, polyolefin) and administered through polyethylene-lined
administration sets.
All patients
should be premedicated prior to paclitaxel administration in order
to prevent severe hypersensitivity reactions. Such premedication
may consist of dexamethasone 20 mg PO administered approximately
12 and 6 hours before paclitaxel, diphenhydramine (or its equivalent)
50 mg IV 30 to 60 minutes prior to paclitaxel, and cimetidine (300
mg) or ranitidine (50 mg) IV 30 to 60 minutes before paclitaxel.
In patients
with carcinoma of the ovary, paclitaxel has been used at several
doses and schedules; however, the optimal regimen is not yet clear
(see CLINICAL PHARMACOLOGY Section.) In patients previously treated
with chemotherapy for ovarian cancer, the recommended regimen is
paclitaxel 135 mg/m2 or 175 mg/m2 administered
intravenously over 3 hours every three weeks.
For patients
with carcinoma of the breast, paclitaxel at a dose of 175 mg/m2
administered intravenously over 3 hours every three weeks has been
shown to be effective after failure of chemotherapy for metastatic
disease or relapse within 6 months of adjuvant chemotherapy.
For the therapy
of patients with solid tumors (ovary and breast), courses of pacliraxel
should not be repeated until the neutrophil count is at least 100,000
cells/mm3. Patients who experience severe neutropenia
(neutrophil <500 cells/mm3 for a week or longer) or
severe peripheral neuropathy during paclitaxel therapy should have
dosage reduced by 20% for subsequent courses of paclitaxel. The
incidence of neurotoxicity
and the severity of neutropenia increase with dose.
Preparation
and Administration Precautions: Paclitaxel is a cytotoxic
anticancer drug and, as with other potentially toxic compounds,
caution should be exercised in handling paclitaxel. The use of gloves
is recommended. If paclitaxel solution contacts the skin, wash the
skin immediately and thoroughly with soap and water. Foillowing
topical exposure, events have included tingling, burning and redness.
If paclitaxel contacts mucous membranes, the membranes should be
flushed thoroughly with water. Upon inhalation, dyspnea, chest pain,
burning eyes, some throat and nausea have been reported.
Given the possibility
of extravasation, it is advisable to closely monitor the infusion
site for possible infiltration during drug administration (See PRECAUTIONS
- Injection Site Reaction Section).
Preparation
for Intravenous Administration: Paclitaxel injection
must be diluted prior to infusion. Paclitaxel injection should be
diluted in 0.9% Sodium Chloride Injection, 5% Dextrose Injection,
5% Dextrose and 0.9% Sodium Chloride Injection, or 5% Dextrose in
Ringer's Injection to a final concentration of 0.3 to 1.2 mg/mL.
The solutions are physically and chemically stable for up to 27
hours at ambient temperature (approximately 25<C) and room lighting
conditions.
Upon preparation,
solutions may show haziness, which is attributed to the formulation
vehicle. No significant losses in potency have been noted following
simulated delivery of the solution through IV tubing containing
an in-line (0.22 micron) filter.
Data collected
for the presence of the extractable plasticizer DEHP [di-(2-ethylhexyl)phthalate}
show that levels increase with time and concentration when dilutions
are prepared in PVC containers. Consequently, the use of plasticized
PVC containers and administration sets is not recommended. Paclitaxel
solutions should be prepared and stored in glass, polypropylene,
or polyolefin containers. Non-PVC containing administration sets,
such as those which are polyethylene-lined, should be used.
Paclitaxel should
be administered through an in-line filter with a microporous membrane
not greater than 0.22 microns. Use of filter devices such as IVEX-2Ò
filters which incorporate short inlet and outlet PVC-coated tubing
has not resulted in significant leaching of DEHP. The
Chemo Dispensing PinTM device or similar devices
with spikes should not be used with vials of paclitaxel injection
since they can cause the stopper to collapse resulting in the loss
of sterile integrity of the paclitaxel solution.
Stability:
Unopened vials of paclitaxel are stable until the date indicated
on the package when stored between 2< to 8<C (36< to 46<F), in the
original package. Freezing does not adversely affect the product.
Upon refrigeration components in the paclitaxel injection may precipitate,
but will redissolve upon reaching room temperature with little or
no agitation. There is no impact on product quality under these
circumstances. If the solution remains cloudy or if an insoluble
precipitate is noted, the vial should be discarded. Solutions for
infusion prepared as recommended are stable at ambient temperature
(approximately 25<C) and lighting conditions for up to 27 hours.
Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit.
How
Supplied:
PACLITAXEL INJECTION
- 30mg/5mL
(6mg/mL) multidose vial individually packaged in a carton.
- 100 mg/16.7
mL (6mg/mL) multidose vial individually packaged in a carton.
- 300 mg/50
mL (6mg/mL) multidose vial individually packaged in a carton.
Storage:
Store the vials in original cartons between 2< and
25<C (36< to 77<F). Retain in the original carton to protect from
light.
Handling
and Disposal: Procedures for proper handling and disposal
of anticancer drugs should be considered. Several guidelines on
this subject have been published.1-7 There is no general agreement
that all of the procedures recommended in the guidelines are necessary
or appropriate.
References:
1. Recommendations for the Safe Handling of Parenteral Antineoplastic
Drugs. NIH Publication No. 83-2621. For sale by the Superintendent
of Documents, US Government Printing Office, Washington, DC 20402.
2. AMA Council
Report. Guidelines for Handling Parenteral Antineoplastics. JAMA
1985; 253 (11): 1590-1592.
3. National
Study Commission on Cytotoxic Exposure - Recommendations for Handling
Cytotoxic Agents. Available from Louis P. Jeffrey, ScD, Chairman,
National Study Commission on Cytotoxic Exposure. Massachusetts College
of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston,
Massachusetts, 02115.
4. Clinical
Oncological Society of Australia. Guidelines and Recommendations
for Safe Handling of Antineoplastic Agents. Med J Australia 1983;
1:426-428.
5. Jones RB,
et al: Safe Handling of Chemotherapeutic Agents: A Report from the
Mount Sinai Medical Center. Ca-A Cancer Journal for Clinicians 1983;
(Sept/Oct) 258-263.
6. American
Society of Hospital Pharmacists Technical Assistance Bulletin on
Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 1990; 47:1033-1049.
7. OSHA Work-Practice
Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic)
Drugs. Am J Hosp Pharm 1986; 43:1193-1204.
8. Shi QW, Oritani
T, Sugiyama T. Three novel bicyclic taxane diterpenoids
with verticillene skeleton from the needles of Chinese yew, Taxus
chinensis var. mairei. Planta Med 1999 May;65(4):356-9
9. Shi QW, Oritani
T, Sugiyama T. Kiyota H. Three novel bicyclic 3,8-secotaxane
diterpenoids from the needles of the chinese yew, taxus chinensis
var. mairei. J Nat Prod 1998 Nov;61(11):1437-40
10. Shi QW,
Oritani T, Sugiyama T. Two bicyclic taxane diterpenoids from the
needles of taxus mairei. Phytochemistry 1999 Feb;50(4):633-6
11. Shi QW,
Oritani T, Sugiyama T, Yamada T. Isolation and structural determination
of a novel bicyclic taxane diterpene from needles of the Chinese
yew, Taxus mairei. Biosci Biotechnol Biochem 1999 Apr;63(4):756-9
12. Liang J,
Kingston DG. Two new taxane diterpenoids from Taxus mairei. J Nat
Prod 1993 Apr;56(4):594-9
13. Shen YC,
Tai HR, Chen CY. New taxane diterpenoids from the roots of Taxus
mairei. J Nat Prod 1996 Feb;59(2):173-6
14. Shen YC,
Chen CY. Taxane diterpenes from Taxus mairei. Planta Med 1997 Dec;63(6):569-70
15. Ma W, Stahlhut
RW, Adams TL, Park GL, Evans WA, Blumenthal SG, Gomez GA, Nieder
MH, Hylands PJ. Yunnanxane and its homologous esters from cell cultures
of Taxus chinensis var. mairei. J Nat Prod 1994 Sep;57(9):1320-4
16. Min ZD,
Jiang H, Liang JY. Studies on the taxane diterpenes of the heartwood
from Taxus mairei. Yao Hsueh Hsueh Pao 1989;24(9):673-7
17. Shen YC,
Chen CY, Kuo YH. A new taxane diterpenoid from Taxus mairei. J Nat
Prod 1998 Jun 26;61(6):838-40
18. Fukushima
M, Takeda J, Fukamiya N, Okano M, Tagahara K, Zhang SX, Zhang DC,
Lee KH. A new taxoid, 19-acetoxytaxagifine, from Taxus
chinensis. J Nat Prod 1999 Jan;62(1):140-2
19. Chen WM,
Zhang PL, Wu B, Zheng QT.
Studies on the chemical constituents of Taxus yunnanensis. Yao Hsueh
Hsueh Pao 1991;26(10):747-54
20, Zhang S, Chen WM, Chen YH. Isolation and identification of two
new taxane diterpenes from Taxus chinensis (Pilger)Rehd. Yao Hsueh
Hsueh Pao 1992;27(4):268-72
21. Zhang S,
Tung-Ling Lee C,
Kashiwada Y, Chen K, Zhang DC,
Lee KH, Yunantaxusin A, a new 11(15-->1)-abeo-taxane from Taxus
yunnanensis. J Nat Prod 1994 Nov;57(11):1580-3
22. Chen YJ,
Chen CY, Shen YC, New taxoids from the seeds of taxus chinensis.
J Nat Prod 1999 Jan;62(1):149-51
23. Liang
JY, Min ZD, Iinuma M, Tanaka T, Mizuno M, Two new antineoplastic
diterpenes from Taxus mairei. Chem Pharm Bull (Tokyo) 1987 Jun;35(6):2613-4
24. Srinivasan
V, Ciddi V, Bringi V,
Shuler ML, Metabolic inhibitors, elicitors, and precursors as tools
for probing yield limitation in taxane production by Taxus chinensis
cell cultures. Biotechnol Prog 1996 Jul-Aug;12(4):457-65
25. Fan J, Tang
g, Shu G, Xu X, On the conservation and regeneration of Taxus resources.
Chung Kuo Chung Yao Tsa Chih
1996 Jul;21(7):389-91, 446
|